We are live on ! Find out more
DGX icon

Quest Diagnostics

1,119 hedge funds and large institutions have $22.3B invested in Quest Diagnostics in 2026 Q2 according to their latest regulatory filings, with 120 funds opening new positions, 434 increasing their positions, 356 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 120 | Existing positions closed: 71

57% more call options, than puts

Call options by funds: $96.4M | Put options by funds: $61.5M

49% more capital inflows, than outflows

Capital inflows: $1.56B | Capital outflows: $1.05B

22% more repeat investments, than reductions

Existing positions increased: 434 | Existing positions reduced: 356

4% more funds holding

Funds holding: 1,077 → 1,119 (+42)

1.57% more ownership

Funds ownership: 93.44% → 95.01% (+1.6%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
1,119
Holders Change
+42
Holders Change %
+3.9%
% of All Funds
13.32%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
120
Increased
434
Reduced
356
Closed
71
Calls
$96.4​M
Puts
$61.5​M
Net Calls
+$34.8​M
Net Calls Change
-⁠$21.6​M

DGX Hedge Fund Activity: Q2 2026 in Review

1,119 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2026, worth a combined $22.3B — up 11% from $20.1B a quarter earlier.

Buyers outnumbered sellers: 120 funds opened new DGX positions and 71 closed out — a net gain of 49 holders — while 434 added to existing stakes and 356 trimmed.

The largest buyer was Boston Partners, adding an estimated $144M. The largest seller was T. Rowe Price Associates, cutting an estimated $167M.

  • 1,119 institutional investors held Quest Diagnostics (DGX) as of Q2 2026, up from 1,077 in Q1 2026.
  • Funds reported $22.3B of Quest Diagnostics stock for Q2 2026, up 11% quarter-over-quarter.
  • 120 funds opened new Quest Diagnostics positions in Q2 2026 and 71 closed out, a net change of +49 holders.
  • The largest Quest Diagnostics buyer in Q2 2026 was Boston Partners, an estimated $144M added.
  • The largest Quest Diagnostics seller in Q2 2026 was T. Rowe Price Associates, an estimated $167M sold.

Based on aggregated 13F filings for Q2 2026.